(Q38447818)

English

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

scientific article published on May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial (English)

1 reference

Europe PubMed Central

3 September 2017

phase II clinical trial

0 references

0 references

prostate carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

3 September 2017

David R Gandara

11

object named as

David R Gandara

1 reference

Europe PubMed Central

3 September 2017

author name string

Primo N Lara

1

1 reference

Europe PubMed Central

3 September 2017

Karen Giselle Chee

2

1 reference

Europe PubMed Central

3 September 2017

Christopher Ruel

4

1 reference

Europe PubMed Central

3 September 2017

Frederick J Meyers

5

1 reference

Europe PubMed Central

3 September 2017

Carl R Gray

6

1 reference

Europe PubMed Central

3 September 2017

Regina Gandour Edwards

7

1 reference

Europe PubMed Central

3 September 2017

Paul H Gumerlock

8

1 reference

Europe PubMed Central

3 September 2017

Przemyslaw Twardowski

9

1 reference

Europe PubMed Central

3 September 2017

James H Doroshow

10

1 reference

Europe PubMed Central

3 September 2017

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

100

1 reference

Europe PubMed Central

3 September 2017

10

1 reference

Europe PubMed Central

3 September 2017

2125-2131

1 reference

Europe PubMed Central

3 September 2017

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

21 January 2018

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Current strategies in the management of hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2/neu expression in cancer: the pathologist as diagnostician or prophet?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 protein expression and gene amplification in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating tumor markers in breast cancer: accepted utilities and novel prospects

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20228

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20228

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38447818&oldid=1760232836"